Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NSRX

Nasus Pharma Ltd

Mar 16 • 04:00PM ET

3.10

-1.90 -38.00 %

Healthcare • Drug Manufacturers - General • Israel • AMEX

Today, 7:35 AMNasus Pharma reports positive Phase 2 topline results for intranasal epinephrine NS002 showing faster delivery than EpiPen

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	66.02%	Shs Outstand	9.06M	Perf Week	-24.57%
Market Cap	26.69M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.00%	Shs Float	2.93M	Perf Month	-44.64%
Enterprise Value	27.38M	PEG	-	EPS next Q	-	Inst Own	0.03%	Short Float	0.30%	Perf Quarter	-52.31%
Income	-	P/S	-	EPS this Y	-129.93%	Inst Trans	-0.06%	Short Ratio	1.39	Perf Half Y	-61.59%
Sales	-	P/B	-	EPS next Y	-13.65%	ROA	-	Short Interest	0.01M	Perf YTD	-66.12%
Book/sh	-0.14	P/C	381.30	EPS next 5Y	-25.38%	ROE	-	52W High	9.99 -68.97%	Perf Year	-
Cash/sh	0.01	P/FCF	-	EPS past 3/5Y	9.82% -	ROIC	-	52W Low	3.99 -22.31%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.63% 13.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.06	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	31.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.06	EPS Q/Q	-	SMA20	-36.63%	Beta	-	Target Price	20.50
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-47.35%	Rel Volume	1291.10	Prev Close	5.00
Employees	5	LT Debt/Eq	-	Earnings	Dec 03	SMA200	-55.41%	Avg Volume	6.36K	Price	3.10
IPO	Aug 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	33.33% -	Trades		Volume	8,216,968	Change	-38.00%

Today 07:30AM	Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold (GlobeNewswire) -38.00%
Mar-09-26 08:30AM	Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study (GlobeNewswire) -15.43%
08:00AM	Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum (GlobeNewswire)
Feb-20-26 08:00AM	Nasus Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.00%
Feb-17-26 08:00AM	Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 (GlobeNewswire)
08:00AM	Loading…
Feb-13-26 08:00AM	Nasus Pharma Announces Closing of $15.0 Million Private Placement (GlobeNewswire) +5.36%
Feb-10-26 11:03PM	Nasus Pharma Announces Pricing of $15.0 Million Private Placement (GlobeNewswire)
Jan-20-26 08:00AM	Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire) -7.52%
Dec-22-25 08:00AM	Nasus Pharma CEO Issues 2025 Letter to Shareholders (GlobeNewswire) -6.56%
Nov-20-25 08:15AM	Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer (GlobeNewswire)
Nov-18-25 08:00AM	Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed (GlobeNewswire)
Nov-06-25 08:00AM	Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder (GlobeNewswire)
Sep-02-25 08:00AM	Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-26-25 08:00AM	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony (GlobeNewswire)
Aug-14-25 04:05PM	Nasus Pharma Announces Closing of Initial Public Offering (GlobeNewswire)
07:30AM	Loading…
Aug-13-25 07:30AM	Nasus Pharma Announces Pricing of $10 Million Initial Public Offering (GlobeNewswire)

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NSRX

Nasus Pharma Ltd

Upgrade your FINVIZ experience